


S1P Pathway Mutations Associate with Disease Stage in DLBCL

on pathway (GNA13/RHOA) effect strongest in GCB subtype; Egress pathway (GNAI2/CXCR4) shows pan-DLBCL

A. Schmitz 2018: GCB-DLBCL


EZB subtype (GNA13/RHOA-enriched)

Late Stage Rate (III-IV)




B. Duke 2017: Pan-DLBCL

All COO subtypes (n=974)



C. Odds Ratios for Late-Stage Disease

Reference: No pathway mutation / Non-EZB



Pathway



Egress



Retention



Retention (proxy)

p < 0.05



FALSE



Retention pathway: GNA13, RHOA, S1PR2, P2RY8, ARHGEF1 | Egress pathway: GNAI2, CXCR4, S1PR1
EZB genetic subtype used as proxy for retention pathway mutations in GCB (Schmitz 2018)